Pluri (PLUR) and Its Rivals Head-To-Head Contrast

Pluri (NASDAQ:PLUR) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Pluri to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, dividends, institutional ownership and earnings.

Profitability

This table compares Pluri and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Pluri Competitors	-12,359.35%	-203.09%	-30.93%

Risk & Volatility

Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Pluri’s competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Earnings and Valuation

This table compares Pluri and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pluri	$1.02 million	-$23.82 million	-0.50
Pluri Competitors	$736.63 million	$13.62 million	-14.73

Pluri’s competitors have higher revenue and earnings than Pluri. Pluri is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for Pluri and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Pluri Competitors	9800	15087	45400	1579	2.54

As a group, “Biotechnology” companies have a potential upside of 104.10%. Given Pluri’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Pluri has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

16.6% of Pluri shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Pluri competitors beat Pluri on 9 of the 13 factors compared.

Pluri Company Profile

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.